We are live on ! Find out more

Nurix Therapeutics

NRIX

Market cap $2.55B

24.60 USD

-0.92

3.61%

At close Updated Sep 15, 3:15 PM EDT

1 day

-3.61%

5 days

-7.03%

1 month

-9.46%

3 months

44.37%

6 months

59.95%

Year to date

36.21%

1 year

183.74%

5 years

-32.38%

10 years

29.41%

About: Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Employees: 357

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 38.9%

Neutral 44.4%

Negative 16.7%

Positive

Zacks Investment Research

5 days ago

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.

Neutral

Seeking Alpha

5 days ago

Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Positive

Zacks Investment Research

6 days ago

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why

Nurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Neutral

GlobeNewsWire

14 days ago

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Tuesday, September 8, 2026, at 3:00 p.m.

Positive

Seeking Alpha

22 days ago

Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case

Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. NRIX's financial runway is extended to ~3.5 years, reducing near-term dilution risk and enabling multi-indication expansion without sacrificing U.S. economics. Bexobrutideg's Phase 1 data show high response rates in CLL/SLL, with a pivotal Phase 3 trial aiming to demonstrate superiority over pirtobrutinib.

Neutral

GlobeNewsWire

26 days ago

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and inflammatory diseases, today announced that Wes Burwell has joined Nurix as its Chief Human Resources Officer (CHRO).

Neutral

GlobeNewsWire

1 month ago

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well as potential royalties, and retains a U.S. co-development and co-promotion option BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following the initiation by its collaborator, Sanofi, of the Phase 1 first-in-human clinical trial of SAR448272/NX-3911, an oral STAT6 degrader.

Neutral

GlobeNewsWire

1 month ago

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor

$Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma$